Αποτελέσματα Αναζήτησης
Researchers have attempted to develop prophylactic and therapeutic vaccines against genital herpes using several vaccine platforms and adjuvants. The adjuvants are primarily used to induce more robust T cell and antibody responses against HSV. As in other vaccines, alum, MF59, MPL, AS04, and QS21 have been used as adjuvants in HSV vaccines
- Vaccines to prevent genital herpes - PMC - PubMed Central (PMC)
An ideal vaccine will prevent both genital lesions and...
- Neutralizing Antibody Kinetics and Immune Protection Against Herpes ...
Abstract. Background: Previously, our group conducted the...
- Vaccines to prevent genital herpes - PMC - PubMed Central (PMC)
An ideal vaccine will prevent both genital lesions and asymptomatic subclinical infection to reduce the risk of inadvertent transmission to partners, will be effective against genital herpes caused by herpes simplex virus types 1 and 2 (HSV-1, HSV-2), and will protect against neonatal herpes.
2 Φεβ 2023 · Background. Previously, our group conducted the Herpevac Trial for Women, a randomized efficacy field trial of type 2 glycoprotein D (gD2) herpes simplex virus (HSV) vaccine adjuvanted with ASO4 in 8323 women. Study participants were selected to be seronegative for HSV-1 and HSV-2.
14 Φεβ 2023 · Abstract. Background: Previously, our group conducted the Herpevac Trial for Women, a randomized efficacy field trial of type 2 glycoprotein D (gD2) herpes simplex virus (HSV) vaccine adjuvanted with ASO4 in 8323 women. Study participants were selected to be seronegative for HSV-1 and HSV-2.
29 Αυγ 2024 · Despite more than 70 years of relentless research, an effective preventive or therapeutic vaccine against HSV has yet to emerge, primarily due to the limited understanding of virus-host interactions, which in turn impedes the identification of effective vaccine targets.
8 Ιουλ 2022 · Daily administration of antiviral medications in persons with recurrent genital herpes decreases lesions, asymptomatic shedding, and transmission to an uninfected partner [11–13]; however, this approach is limited by the cost and inconvenience of daily therapy and will likely have limited overall impact on incidence and prevalence in an infectio...
20 Αυγ 2014 · The focus of genital herpes vaccine trials has been on prevention using herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) alone or combined with glycoprotein B. These prevention trials did not achieve their primary end points. However, subset analyses reported some positive outcomes in each study.
